Skip Navigation


Rheumatology Advance Access originally published online on September 26, 2006
Rheumatology 2007 46(2):183-184; doi:10.1093/rheumatology/kel332
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow CME/CE:
Take the course for this article:
 Rheumatology Fourth Quarter 2006 Quiz
Right arrow All Versions of this Article:
46/2/183    most recent
kel332v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (1)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Kelly, C.
Right arrow Articles by Hamilton, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kelly, C.
Right arrow Articles by Hamilton, J.
Related Collections
Right arrow Rheumatoid Arthritis
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2006. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org

EDITORIALS

What kills patients with rheumatoid arthritis?

C. Kelly and J. Hamilton

Department of Medicine, Queen Elizabeth Hospital, NHS Foundation Trust, Sheriff Hill, Gateshead NE40 3LU, UK

Correspondence to: C. Kelly, Department of Medicine, Queen Elizabeth Hospital, NHS Foundation Trust, Sheriff Hill, Gateshead NE40 3LU, UK. E-mail: clive.kelly@ghnt.nhs.uk

The first 150 words of the full text of this article appear below.

Patients with rheumatoid arthritis (RA) die at a younger age than their peers in most hospital series [1], while an increase in standardized mortality rate (SMR) has not been a consistent feature in recent studies of RA patients from date of diagnosis (inception cohorts) [2]. The reasons for this apparent discrepancy are likely to be the presence of more severe disease in hospital-based series and the advent of earlier and more effective treatment in recent years. However, an increased mortality from vascular disease in RA has been consistently reported in both established and inception studies [1, 3], and an increased SMR for respiratory disease and lymphoreticular cancers has also been recognized in most series.

A detailed study in this month's issue addresses the important question of whether patients with RA treated early and actively with disease-modifying anti-rheumatic drugs (DMARDs) still have increased mortality . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?